View of Daratumumab (Darzalex SC) | Canadian Journal of Health Technologies
MEZI Combo Therapy for Relapsed Myeloma | Int'l Myeloma Fn
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients - Nooka - 2019 - Cancer - Wiley Online Library
Genmab Announces Financial Results for the First Quarter of 2016
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
PDF) Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
SQ daratumumab bortezomib cyclophosphamide dex in pts with newly diagnosed light chain amyloidosis
Multiple Myeloma Hub on X: "CONGRESS | #ASH19 |Nizar Bahlis, @nbahlis, resports from Phase 1/2 of Venetoclax + Dara and Dex, +/- Velcade , in R/R MM. GR 3/4 AEs: VenDd: neutropenia,
PDF) Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk | Journal of Hematology & Oncology | Full Text
Multiple Myeloma RF on X: "Late breaking abstract session on Perseus PH 3 EMN trial. Darzalex- Velcade-Revlimid-Dex (DVRd) vs VRd in transplant eligible newly diagnosed #myeloma. Impressive results with DVRd in PFS
IFM 2020 - Isa-RVd Vs Isa-Rd - Multiple Myeloma Clinical Trials
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
CASSIOPEIA - Dara-VTd - Multiple Myeloma Clinical Trials
The ADVANCE trial - Dara-KRd vs KRd vs VRd
PDF) Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
SQ daratumumab bortezomib cyclophosphamide dex in pts with newly diagnosed light chain amyloidosis - YouTube
Cancers | Free Full-Text | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
Mieloma Multiplo x Sito REV 22 dicembre 2020
For Multiple Myeloma
PDF) Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview SUPERSEDED | eviQ
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - ScienceDirect
